Ovarian Cancer - Pipeline Review, H2 2017

Date: December 29, 2017
Pages: 2232
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O542E62C73FEN
Leaflet:

Download PDF Leaflet

Ovarian Cancer - Pipeline Review, H2 2017
Ovarian Cancer - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H2 2017, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 2, 14, 141, 144, 7, 221, 26 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 12, 45 and 8 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Ovarian Cancer - Overview
Ovarian Cancer - Therapeutics Development
Ovarian Cancer - Therapeutics Assessment
Ovarian Cancer - Companies Involved in Therapeutics Development
Ovarian Cancer - Drug Profiles
Ovarian Cancer - Dormant Projects 2130
Ovarian Cancer - Discontinued Products 2152
Ovarian Cancer - Product Development Milestones 2157
Appendix 2169

LIST OF TABLES

Number of Products under Development for Ovarian Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Ovarian Cancer - Pipeline by 3-V Biosciences Inc, H2 2017
Ovarian Cancer - Pipeline by 4SC AG, H2 2017
Ovarian Cancer - Pipeline by AB Science SA, H2 2017
Ovarian Cancer - Pipeline by AbbVie Inc, H2 2017
Ovarian Cancer - Pipeline by AbGenomics International Inc, H2 2017
Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2017
Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H2 2017
Ovarian Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H2 2017
Ovarian Cancer - Pipeline by Advantagene Inc, H2 2017
Ovarian Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
Ovarian Cancer - Pipeline by Aeterna Zentaris Inc, H2 2017
Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2017
Ovarian Cancer - Pipeline by AlfaSigma SpA, H2 2017
Ovarian Cancer - Pipeline by Alkermes Plc, H2 2017
Ovarian Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2017
Ovarian Cancer - Pipeline by Almac Discovery Ltd, H2 2017
Ovarian Cancer - Pipeline by Alpha Cancer Technologies Inc, H2 2017
Ovarian Cancer - Pipeline by Alteogen Inc, H2 2017
Ovarian Cancer - Pipeline by Altor BioScience Corp, H2 2017
Ovarian Cancer - Pipeline by Ambrx Inc, H2 2017
Ovarian Cancer - Pipeline by Amgen Inc, H2 2017
Ovarian Cancer - Pipeline by Amunix Operating Inc, H2 2017
Ovarian Cancer - Pipeline by Anavex Life Sciences Corp, H2 2017
Ovarian Cancer - Pipeline by ANP Technologies Inc, H2 2017
Ovarian Cancer - Pipeline by AntiCancer Inc, H2 2017
Ovarian Cancer - Pipeline by Antigen Express Inc, H2 2017
Ovarian Cancer - Pipeline by Antoxis Ltd, H2 2017
Ovarian Cancer - Pipeline by Aphios Corp, H2 2017
Ovarian Cancer - Pipeline by Aposense Ltd, H2 2017
Ovarian Cancer - Pipeline by Aprea AB, H2 2017
Ovarian Cancer - Pipeline by arGEN-X BV, H2 2017
Ovarian Cancer - Pipeline by ARMO Biosciences Inc, H2 2017
Ovarian Cancer - Pipeline by Armour Therapeutics Inc, H2 2017
Ovarian Cancer - Pipeline by ArQule Inc, H2 2017
Ovarian Cancer - Pipeline by Array BioPharma Inc, H2 2017
Ovarian Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2017
Ovarian Cancer - Pipeline by Astellas Pharma Inc, H2 2017
Ovarian Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2017
Ovarian Cancer - Pipeline by AstraZeneca Plc, H2 2017
Ovarian Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2017
Ovarian Cancer - Pipeline by Athenex Inc, H2 2017
Ovarian Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Ovarian Cancer - Pipeline by Avipep Pty Ltd, H2 2017
Ovarian Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2017
Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H2 2017
Ovarian Cancer - Pipeline by Bayer AG, H2 2017
Ovarian Cancer - Pipeline by BeiGene Ltd, H2 2017
Ovarian Cancer - Pipeline by Bio-Path Holdings Inc, H2 2017
Ovarian Cancer - Pipeline by BioCancell Ltd, H2 2017
Ovarian Cancer - Pipeline by BioMoti Ltd, H2 2017
Ovarian Cancer - Pipeline by Bionomics Ltd, H2 2017
Ovarian Cancer - Pipeline by BioNTech AG, H2 2017
Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H2 2017
Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Ovarian Cancer - Pipeline by Boston Biomedical Inc, H2 2017
Ovarian Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017
Ovarian Cancer - Pipeline by Caladrius Biosciences Inc, H2 2017
Ovarian Cancer - Pipeline by Calithera Biosciences Inc, H2 2017
Ovarian Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2017
Ovarian Cancer - Pipeline by Cavion LLC, H2 2017
Ovarian Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017
Ovarian Cancer - Pipeline by Celgene Corp, H2 2017
Ovarian Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017
Ovarian Cancer - Pipeline by Celleron Therapeutics Ltd, H2 2017
Ovarian Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2017

LIST OF FIGURES

Number of Products under Development for Ovarian Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

3-V Biosciences Inc
4SC AG
AB Science SA
AbbVie Inc
AbGenomics International Inc
Adaptimmune Therapeutics Plc
Adgero Biopharmaceuticals Holdings Inc
Advanced Cancer Therapeutics LLC
Advantagene Inc
Advenchen Laboratories LLC
Aeterna Zentaris Inc
Alethia Biotherapeutics Inc
AlfaSigma SpA
Alkermes Plc
Allist Shanghai Pharmaceutical Technology Co Ltd
Almac Discovery Ltd
Alpha Cancer Technologies Inc
Alteogen Inc
Altor BioScience Corp
Ambrx Inc
Amgen Inc
Amunix Operating Inc
Anavex Life Sciences Corp
ANP Technologies Inc
AntiCancer Inc
Antigen Express Inc
Antoxis Ltd
Aphios Corp
Aposense Ltd
Aprea AB
arGEN-X BV
ARMO Biosciences Inc
Armour Therapeutics Inc
ArQule Inc
Array BioPharma Inc
Arrien Pharmaceuticals LLC
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Athenex Inc
AVEO Pharmaceuticals Inc
Avipep Pty Ltd
Basilea Pharmaceutica Ltd
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Bio-Path Holdings Inc
BioCancell Ltd
BioMoti Ltd
Bionomics Ltd
BioNTech AG
Biscayne Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Caladrius Biosciences Inc
Calithera Biosciences Inc
CASI Pharmaceuticals Inc
Cavion LLC
CBT Pharmaceuticals Inc
Celgene Corp
Celldex Therapeutics Inc
Celleron Therapeutics Ltd
Cellular Biomedicine Group Inc
Celon Pharma SA
Celprogen Inc
Celsion Corp
Celyad SA
Ceronco Biosciences
CerRx Inc
Chipscreen Biosciences Ltd
Cielo Therapeutics Inc
Clovis Oncology Inc
CohBar Inc
Coherus BioSciences Inc
Commence Bio Inc
Compliment Corp
Corcept Therapeutics Inc
Critical Outcome Technologies Inc
Cyclacel Pharmaceuticals Inc
CytomX Therapeutics Inc
Cytori Therapeutics Inc
CZ BioMed Corp
DAE HWA Pharmaceutical Co Ltd
Deciphera Pharmaceuticals LLC
DEKK-TEC Inc
DelMar Pharmaceuticals Inc
Dr. Reddy's Laboratories Ltd
Ecrins Therapeutics SAS
Eisai Co Ltd
Eli Lilly and Co
Endocyte Inc
EntreChem SL
Epigen Biosciences Inc
EpiThany Inc
Epizyme Inc
Esperance Pharmaceuticals Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Fate Therapeutics Inc
Forty Seven Inc
Fujifilm Holdings Corporation
Galena Biopharma Inc
GamaMabs Pharma SA
Gene Techno Science Co Ltd
Genelux Corp
Genentech Inc
Genisphere LLC
Genmab A/S
Genor BioPharma Co Ltd
Gilead Sciences Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
GlycoNex Inc
Glycotope GmbH
GP Pharm SA
Gradalis Inc
GW Pharmaceuticals Plc
Halozyme Therapeutics Inc
Hanmi Pharmaceuticals Co Ltd
Hemispherx Biopharma Inc
Horizon Pharma Plc
Ideaya Biosciences Inc
Ignyta Inc
Ildong Pharmaceutical Co Ltd
IMMD Inc
Immix BioPharma Inc
Immune Design Corp
Immune Pharmaceuticals Inc
Immunocore Ltd
ImmunoGen Inc
Immunomedics Inc
Immunovaccine Inc
IMPACT Therapeutics Inc
Imugene Ltd
Incyte Corp
Innate Pharma SA
Innovation Pharmaceuticals Inc
Inovio Pharmaceuticals Inc
Inventiva
Iovance Biotherapeutics Inc
ITUS Corp
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Juno Therapeutics Inc
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Kringle Pharma Inc
Kyowa Hakko Kirin Co Ltd
La Jolla Pharmaceutical Company
Laboratoire HRA Pharma SAS
Lantern Pharma Inc
LATITUDE Pharmaceuticals Inc
LegoChem Biosciences Inc
Lidds AB
Lixte Biotechnology Holdings Inc
Loxo Oncology Inc
Lycera Corp
Lymphocyte Activation Technologies SA
MabVax Therapeutics Holdings Inc
MacroGenics Inc
Madrigal Pharmaceuticals Inc.
Mateon Therapeutics Inc
MaxiVAX SA
Mebiopharm Co Ltd
MediaPharma SRL
MedImmune LLC
Medivir AB
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Mersana Therapeutics Inc
Merus NV
Microlin Bio Inc
Millennium Pharmaceuticals Inc
Minerva Biotechnologies Corp
Moleculin Biotech Inc
MolMed SpA
Monopar Therapeutics LLC
Morphotek Inc
Mycenax Biotech Inc
NanoVector Inc
NantKwest Inc
Natco Pharma Ltd
NBE-Therapeutics AG
Nektar Therapeutics
Neovacs SA
Nerviano Medical Sciences Srl
Neurimmune Holding AG
NewLink Genetics Corp
Northwest Biotherapeutics Inc
Novartis AG
NovaTarg Therapeutics Inc
Noviga Research AB
Noxopharm Ltd
NuCana Plc
Oasmia Pharmaceutical AB
OBI Pharma Inc
Omeros Corp
Omnitura Therapeutics Inc
OncBioMune Pharmaceuticals Inc
Oncobiologics Inc
Oncodesign SA
Oncolix Inc
Oncolytics Biotech Inc
OncoMed Pharmaceuticals Inc
OncoResponse Inc
OncoTartis Inc
OncoTherapy Science Inc
Oncternal Therapeutics Inc
Ono Pharmaceutical Co Ltd
Opsona Therapeutics Ltd
Optimum Therapeutics LLC
ORCA Therapeutics BV
Oric Pharmaceuticals Inc
OSE Immunotherapeutics
Oxford BioMedica Plc
Pangaea Biotech SL
Patrys Ltd
PDS Biotechnology Corp
PEP-Therapy SAS
Pfizer Inc
Pharma Mar SA
PharmAust Ltd
Pharmicell Co Ltd
Plexxikon Inc
Polaris Pharmaceuticals Inc
Precision Biologics Inc
Propanc Biopharma Inc
Protheragen Inc
PsiOxus Therapeutics Ltd
PTC Therapeutics Inc
Puma Biotechnology Inc
Radius Health Inc
Recepta Biopharma SA
Rexahn Pharmaceuticals Inc
Rgenix Inc
Richter Gedeon Nyrt
Rigel Pharmaceuticals Inc
Rosetta Genomics Ltd
RS Research
Rubicon Biotechnology Inc
RXi Pharmaceuticals Corp
Samumed LLC
Sanofi
Sanofi Pasteur SA
SATT North SAS
Scancell Holdings Plc
Sellas Life Sciences Group Ltd
Senhwa Biosciences Inc
Sequoia Sciences Inc
Siamab Therapeutics Inc
Sierra Oncology Inc
Sigma-Tau SpA
Sillajen Biotherapeutics
Sitka Biopharma Inc
Soricimed Biopharma Inc
Sorrento Therapeutics Inc
Sotio AS
Starpharma Holdings Ltd
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Supratek Pharma Inc
Susavion Biosciences Inc
Sutro Biopharma Inc
Syndax Pharmaceuticals Inc
Synthon Holdings BV
Syros Pharmaceuticals Inc
Tactiva Therapeutics LLC
Taiho Pharmaceutical Co Ltd
Takis Srl
TapImmune Inc
Targovax ASA
TC BioPharm Ltd
Tesaro Inc
The Female Health Company
TheraTarget Inc
Tocagen Inc
TRACON Pharmaceuticals Inc
Transgene SA
TVAX Biomedical Inc
Tyrogenex Inc
Unleash Immuno Oncolytics Inc
ValiRx Plc
Vascular Biogenics Ltd
Vectorite Biomedical Inc
Verastem Inc
VG Life Sciences Inc
ViiV Healthcare UK Ltd
ViraTherapeutics GmbH
Vyriad Inc
Zymeworks Inc
Skip to top


Ask Your Question

Ovarian Cancer - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: